Norovirus Vaccine Candidate for Children Results Expected in 2024

HilleVax, Inc. today announced the completion of enrollment of the NEST-IN1 clinical trial for children, with over 3,000 subjects enrolled in six countries.

NEST-IN1 is the company’s ongoing Phase 2b trial for HIL-214, its investigational virus-like particle-based vaccine candidate for preventing moderate-to-severe norovirus-related acute gastroenteritis in infants (AGE). 

This study was last updated on April 7, 2023. Topline safety and clinical efficacy data from NEST-IN1 are expected in the first quarter of 2024.

“I am excited to announce the completion of enrollment of our NEST-IN1 study, which brings us one step closer to topline results in the first quarter of 2024,” said Rob Hershberg, MD, Ph.D., Chairman and CEO of HilleVax, in a press release on April 25, 2023.

“There are no approved vaccines for norovirus, which results in approximately 700 million cases of acute gastroenteritis and 200,000 deaths per year.”

Norovirus is a very contagious virus that causes vomiting and diarrhea. Anyone can get infected and sick with norovirus, says the U.S. CDC.

Globally, norovirus is estimated to result in approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year.